Shin Nippon Biomedical Laboratories Ltd

Research Shin Nippon Biomedical Laboratories Ltd (YB3) on Bullrun: market cap EUR 314.32M, P/E 12.8, dividend yield 3.7%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 314.32M; P/E is 12.8; dividend yield is 3.7%.

Peer valuation comparison

Latest P/E is 12.8x versus a Healthcare sector median of 24.46x (47.7% below).

Latest dividend yield is 3.71% versus a Healthcare sector median of 2.11% (75.8% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2026JPY 32.52BJPY 4.57BJPY 2.99B49.9%109.69JPY 18.54BJPY 41.26BJPY 43.12B
FY2025JPY 32.41BJPY 4.92B-JPY 3.90B52.3%118.29JPY 12.03BJPY 34.47BJPY 40.02B
FY2024JPY 26.45BJPY 5.53B-JPY 6.50B54.0%132.86JPY 10.27BJPY 26.19BJPY 34.11B
FY2023JPY 25.09BJPY 6.06B-JPY 951.70M52.0%145.56JPY 10.53BJPY 18.76BJPY 26.21B
FY2022JPY 17.75BJPY 7.13BJPY 4.34B54.6%171.2JPY 6.63BJPY 9.14BJPY 19.56B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-23EUR 314.32M12.83.6%0.27

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.27 EUR, yield 3.7%.

YearDividends/share
FY20260.16 JPY
FY20250.27 JPY
FY20240.27 JPY
FY20230.27 JPY
FY20220.33 JPY

About Shin Nippon Biomedical Laboratories Ltd

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Shin Nippon Biomedical Laboratories Ltd's market cap?

Shin Nippon Biomedical Laboratories Ltd's market capitalization is EUR 314.32M.

What is Shin Nippon Biomedical Laboratories Ltd's P/E ratio?

Shin Nippon Biomedical Laboratories Ltd's price-to-earnings (P/E) ratio is 12.8.

Does Shin Nippon Biomedical Laboratories Ltd pay a dividend?

Shin Nippon Biomedical Laboratories Ltd has a dividend yield of 3.7%.

What does Shin Nippon Biomedical Laboratories Ltd do?

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies.